How the Wegovy step-up schedule works — and what to expect at each stage

Why does the Wegovy dose increase in stages rather than starting high?

The short answer is tolerability. Semaglutide slows gastric emptying and acts on appetite-regulating receptors in the brain, and both effects are dose-dependent. Jump straight to 2.4 mg and most people feel quite unwell. Nausea, vomiting, and loose stools are the most commonly reported side effects during Wegovy treatment, and they cluster heavily around dose changes.

The step-up schedule (0.25 mg for four weeks, then 0.5 mg, 1.0 mg, 1.7 mg and finally 2.4 mg, each for roughly four weeks) gives your system time to adapt at each rung before moving up. Clinical trial data published in the New England Journal of Medicine (STEP 1) showed participants following this schedule achieved around 15% average body-weight reduction over 68 weeks, which suggests the measured approach does not blunt the eventual result. The GI side effects that do occur tend to be most noticeable in the first week or two after each increase, then settle.

Practically, this means the first pen is not the treatment in any meaningful therapeutic sense. It is closer to an introduction. If you are hoping to see the scale move in the first four weeks, you may find that frustrating, and it is worth knowing that in advance.

What does the step-up process look like in practice at each stage?

Each four-week period corresponds to one Wegovy pen. The pen arrives pre-set at that week's dose, you do not dial anything yourself. When your order arrives via DPD in plain, unbranded packaging, the pen inside is already calibrated to the strength your prescriber has approved for that cycle.

At 0.25 mg most people notice little beyond mild nausea, if anything. The appetite effect at this dose is modest. By 0.5 mg and 1.0 mg some people begin to feel a noticeable reduction in hunger, and GI symptoms may increase transiently after each step. The 1.7 mg dose is the last step before standard maintenance; this is often where side effects are most pronounced, because the jump to 1.7 mg is one of the larger increments in the schedule.

At 2.4 mg (the standard maintenance dose) the full appetite-suppressing effect is established. For people who reach this dose without significant side effects, the full dose-step breakdown explains each transition in more detail. For those using the 7.2 mg pen, titration still starts at 0.25 mg; the prescriber determines when and whether progression to 7.2 mg is appropriate. The NHS semaglutide medicines page gives a clear patient-level overview of what each dose involves.

Can you slow down or pause the step-up if side effects are difficult?

Yes, and this is exactly the kind of decision that should involve your prescriber rather than be made unilaterally. Staying at a lower dose for longer than the standard four weeks is a recognised clinical option when GI symptoms are severe enough to affect daily life. It is not a failure. Moving more slowly through the schedule does not change the endpoint; it just extends the timeline to get there.

Similarly, if you have missed a dose, the guidance on what to do depends on how much time has passed since your missed injection, detail that is specific to your situation and covered in the Patient Information Leaflet. Do not double up without speaking to your prescriber first. Our FAQs cover some of the most common questions about managing a dose change, and our support team is available seven days a week.

The guidance on moving up a dose goes further on the practical and clinical considerations involved in each step. For those weighing whether the step-up process feels manageable alongside their lifestyle, that page is worth reading before starting.

What about the 7.2 mg dose, who is it for, and how does the step-up reach it?

The MHRA approved Wegovy 7.2 mg as a maintenance dose in January 2026, and the dedicated single-dose pen received approval on 14 April 2026. It is licensed for adults with a BMI of 30 or above, the cardiovascular indication does not apply to this dose format. Trial data at 7.2 mg showed around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide 15 mg results.

The route to 7.2 mg still begins at 0.25 mg. There is no shortcut through the titration schedule, and the 7.2 mg dose is only considered once a patient has reached and tolerated 2.4 mg. Whether progression to 7.2 mg is clinically appropriate is a prescriber decision, not something determined by the patient requesting it. If you are curious about the maximum dose Wegovy reaches and what the evidence says about it, that page covers the detail.

Thinking about what Wegovy treatment might cost over a full titration period is a reasonable question, you can find a factual breakdown on the Wegovy cost page. For people ready to find out whether they are clinically eligible, a free consultation with our prescribers is the first step. Our clinical team is GPhC-registered and reviews every consultation personally.